Skip to main content

Table 1 Association between RRM2 expression and clinicopathologic characteristics (logistic regression)

From: RRM2 silencing suppresses malignant phenotype and enhances radiosensitivity via activating cGAS/STING signaling pathway in lung adenocarcinoma

Clinical characteristics Total (N) Odds ratio (OR) in RRM2 expression p-value
Age 494   
 ≤ 65 vs. > 65   0.7464644 (0.5234463–1.06287) 0.1053727
Gender 513   
 Male vs. Female   1.357798 (0.9591132–1.925223) 0.08510176
Stage 505   
 II vs. I   1.55754 (1.014021–2.399717) 0.04346904*
 III vs. I   2.180556 (1.327597–3.627003) 0.002300152**
 IV vs. I   3.019231 (1.30853–7.578007) 0.01244337*
T 510   
 T2 vs. T1   1.959701 (1.329787–2.902402) 0.0007191007***
 T3 vs. T1   1.326567 (0.6885868–2.545255) 0.3947867
 T4 vs. T1   1.674959 (0.6424348–4.427256) 0.2882927
N 501   
 N2 vs. N1   1.75431 (1.108522–2.796568) 0.0170222*
 N3 vs. N1   2.50069 (1.487095–4.295968) 0.0006760279***
 N4 vs. N1   1.275862 (0.05016816–32.44753) 0.8636424
M 369   
 M1 vs. M0   2.252246 (0.9743585–5.647803) 0.06628612